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ORIGINAL RESEARCH

Measurement of Low-Density Lipoprotein Cholesterol Levels
in Primary and Secondary Prevention Patients:
Insights From the PALM Registry
Angela M. Lowenstern, MD; Shuang Li, MS; Ann Marie Navar, MD, PhD; Veronique L. Roger, MD, MPH; Jennifer G. Robinson, MD, MPH;
Anne C. Goldberg, MD; Salim S. Virani, MD, PhD; L. Veronica Lee, MD; Peter W. F. Wilson, MD; Michael J. Louie, MD, MPH, MSc;
Eric D. Peterson, MD, MPH; Tracy Y. Wang, MD, MHS, MSc

Background-—The 2013 American College of Cardiology/American Heart Association Guideline on the Treatment of Blood
Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults recommended testing low-density lipoprotein cholesterol (LDLC) to identify untreated patients with LDL-C ≥190 mg/dL, assess lipid-lowering therapy adherence, and consider nonstatin
therapy. We sought to determine whether clinician lipid testing practices were consistent with these guidelines.
Methods and Results-—The PALM (Patient and Provider Assessment of Lipid Management) registry enrolled primary and secondary
prevention patients from 140 US cardiology, endocrinology, and primary care ofﬁces in 2015 and captured demographic data, lipid
treatment history, and the highest LDL-C level in the past 2 years. Core laboratory lipid levels were drawn at enrollment. Among
7627 patients, 2787 (36.5%) had no LDL-C levels measured in the 2 years before enrollment. Patients without chart-documented
LDL-C levels were more often women, nonwhite, uninsured, and non–college graduates (all P<0.01). Patients without prior lipid
testing were less likely to receive statin treatment (72.6% versus 76.0%; P=0.0034), a high-intensity statin (21.5% versus 24.3%;
P=0.016), nonstatin lipid-lowering therapy (24.8% versus 27.3%; P=0.037), and had higher core laboratory LDL-C levels at enrollment
(median 97 versus 92 mg/dL; P<0.0001) than patients with prior LDL-C testing. Of 166 individuals with core laboratory LDL-C levels
≥190 mg/dL, 36.1% had no LDL-C measurement in the prior 2 years, and 57.2% were not on a statin at the time of enrollment.
Conclusions-—In routine clinical practice, LDL-C testing is associated with higher-intensity lipid-lowering treatment and lower
achieved LDL-C levels. ( J Am Heart Assoc. 2018;7:e009251. DOI: 10.1161/JAHA.118.009251.)
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L

ow-density lipoprotein cholesterol (LDL-C)-lowering therapy has been shown to reduce atherosclerotic cardiovascular disease (ASCVD) risk in patients with and without
ASCVD.1–7 The Adult Treatment Panel III guidelines set LDL-C
and non–high-density lipoprotein cholesterol (HDL-C) level
targets to guide lipid-lowering therapy selection and dosing.8
The 2013 American College of Cardiology (ACC)/American
Heart Association (AHA) Guideline on the Treatment of Blood
Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in
Adults shifted away from numeric LDL-C targets to focus

more broadly on a patient’s ASCVD risk and potential to
beneﬁt from therapy.9 The 2013 guideline continues to
recommend LDL-C testing for several reasons: (1) to identify
individuals with untreated primary LDL-C levels ≥190 mg/dL;
(2) to assess treatment response and adherence to statin and
lifestyle therapy; and (3) to guide the consideration of
nonstatin therapy.9,10
The PALM (Patient and Provider Assessment of Lipid
Management) registry was designed to observe lipid management practice patterns after the implementation of the 2013
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What Is New?
• The 2013 American College of Cardiology/American Heart
Association (ACC/AHA) Guideline on the Treatment of Blood
Cholesterol to Reduce Atherosclerotic Risk in Adults
transitioned from a focus on achieving an low-density
lipoprotein cholesterol target to treatment based on a
patient’s overall atherosclerotic disease risk.
• This study explores clinician use of blood lipid level
evaluation following the release of the 2013 ACC/AHA
guidelines.
• Over a third of patients did not have low-density lipoprotein
cholesterol testing in the 2 years before enrollment.
• Patients without low-density lipoprotein cholesterol testing
were less likely to be treated with a statin medication, a
high-intensity statin, and nonstatin lipid-lowering therapy.

What Are the Clinical Implications?
• Within the context of the 2013 ACC/AHA guideline, lipid
testing may help to optimize guideline-recommended statin
use and dosing.

Downloaded from http://ahajournals.org by on January 9, 2019

ACC/AHA cholesterol guideline.11 This nationwide, crosssectional registry allowed us to examine (1) the prevalence of
LDL-C testing among primary and secondary prevention
patients, (2) provider and patient characteristics associated
with lipid testing, (3) whether lipid testing was associated with
greater adherence to ACC/AHA guideline–recommended
lipid-lowering therapy use, and (4) the association between
lipid testing and achievement of lower LDL-C levels. We
hypothesized that lipid testing would be associated with
greater adherence to ACC/AHA guideline–recommended
therapy and lower LDL-C levels.

Methods
Study Population
The PALM registry enrolled 7938 adults on statins, adults at
high risk of ASCVD, and adults with prior ASCVD from 140
cardiology, primary care, and endocrinology practices in the
United States. Detailed design, rationale, inclusion, and
exclusion criteria for the PALM registry have been published
previously.11 The data, analytic methods, and study materials
will not be made available to other researchers for purposes
of reproducing the results or replicating the procedure.
Enrollment was conducted between May 27, 2015, and
November 12, 2015. All participants provided signed informed
consent to participate. Each site obtained institutional review
board approval for participation.
DOI: 10.1161/JAHA.118.009251

Chart abstractions and core laboratory lipid panels were
conducted to assess current lipid management. For this
analysis, participants were included if they underwent phlebotomy for core laboratory lipid measurement at enrollment in
the study (n=7722). Subjects were excluded if they were
missing valid lipid core laboratory data (n=91) or data on prior
ASCVD history (n=4). This resulted in a ﬁnal study population
of 7627 primary and secondary patients enrolled at 140
practices.

Data Collection and Deﬁnitions
At study initiation and before any patient enrollment,
providers at each participating site completed surveys that
collected provider and practice characteristics. For each
enrolled patient, sites retrospectively reviewed medical
records to determine whether lipid testing was previously
performed. Patients were deﬁned as having clinician-ordered
lipid testing if they had LDL-C test results documented in the
medical record within the 2 years before enrollment, regardless of whether these tests were performed at the study site
or elsewhere, with results available to the treating physician.
Data for the most recent LDL-C measurement, as well as the
highest LDL-C measurement in the past 2 years, were entered
into the data collection form. Additionally, chart review
collected detailed sociodemographic and medical history for
each enrolled patient, as well as current statin use and dosing
intensity. Enrolled patients were asked if they knew their
cholesterol level. On the day of enrollment, each patient
underwent phlebotomy to analyze total cholesterol, direct
LDL-C, HDL-C, and triglyceride levels that were performed by
a central core laboratory.
Treatment with guideline-recommended statin dosing
intensity was deﬁned by certain criteria. A high-intensity
statin was recommended for patients with at least 1 of the
following criteria: (1) known ASCVD and aged ≤75 years;
(2) LDL-C ≥190 mg/dL; or (3) diabetes mellitus with
estimated 10-year ASCVD risk ≥7.5%, aged 40–75 years,
and LDL-C ≥70 mg/dL. A statin of at least moderate intensity
was recommended for patients without indication for highintensity statin and (1) aged 40 to 75 years, diabetes mellitus,
and estimated 10-year ASCVD risk <7.5% with LDL-C
≥70 mg/dL or LDL-C <70 mg/dL currently on statin therapy;
(2) clinical ASCVD and aged >75; or (3) no diabetes mellitus
and 10-year ASCVD risk ≥7.5% with LDL-C ≥70 mg/dL or
LDL-C <70 mg/dL currently on statin therapy.

Statistical Analysis
Patients were categorized based on the presence or absence
of medically documented lipid testing with at least 1 LDL-C
value and the highest LDL-C value in the 2 years before study
Journal of the American Heart Association
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Results
Prevalence of Lipid Testing
Among the ﬁnal study population of 7627 patients, 4840
(63.5%) had a documented measurement of LDL-C in the
medical record in the 2 years before enrollment.
DOI: 10.1161/JAHA.118.009251

Preenrollment LDL-C testing rates were lower among primary
prevention than secondary prevention patients (61.8% versus
65.6%; P<0.001). Age was not signiﬁcantly different between
those with and without lipid testing, but patients without LDLC measurements were more often women, nonwhite, uninsured, and non–college graduates compared with patients
who had known LDL-C results (Table 1). Tested patients were
more likely to have chronic kidney disease (10.8% versus
7.1%; P<0.001) but less likely to have other cardiovascular
risk factors such as diabetes mellitus (37.7% versus 40.0%;
P=0.04), hypertension (76.3% versus 79.3%; P=0.002), and
habitual smoking (10.6% versus 18.3%; P<0.001) than
patients without lipid testing (Table 1). As expected, patients
with LDL-C testing documented in the chart were more likely
to report knowing their cholesterol level (77.0% versus 64.2%;
P<0.001).

Provider Characteristics Associated With Testing
Provider characteristics were also associated with a patient’s
likelihood for LDL-C testing. Patients seen by endocrinologists
had the highest rate of recent lipid testing (74.4%), followed
by cardiologists (67.2%), then primary care physicians (64.7%)
(Figure 1; P for trend=0.008). Patients seen at practices in
urban locations were more likely to undergo lipid testing than
at practices in rural locations (65.5% versus 44.5%; P<0.001).
Patients seen by providers who reported primarily using the
2013 ACC/AHA guidelines to guide lipid management were
more likely to have had lipid testing than those seen by
providers who did not (68.2% versus 60.6%; P<0.001).

Association Between Testing and Statin Use
Among the 5909 patients with a guideline indication for statin
treatment, those with LDL-C testing in the past 2 years were
more likely to be taking a statin at the time of their visit
(76.0% versus 72.6%; P=0.003). This association persisted
after multivariable adjustment: odds ratio, 1.23; 95% conﬁdence interval, 1.01–1.50; P=0.043). Among patients without
a chart-documented LDL-C measurement who were indicated
for but not on statin treatment, only 91 (15.4%) were
previously treated with a statin. Among patients indicated
for statin therapy, patients with prior LDL-C testing were more
likely to be treated with a high-intensity statin (24.3% versus
21.5%; P=0.016) or a nonstatin lipid-lowering therapy (27.3%
versus 24.8%; P=0.037) (Figure 2).
A total of 2627 patients met a guideline indication for
primary prevention statin therapy, and 3282 patients met an
indication for secondary prevention statin therapy. Among
patients indicated for primary prevention statin therapy, 955
(36.4%) were not on a statin at the time of enrollment (Table 2),
and of the patients on a statin, 713 (42.6%) were prescribed a
Journal of the American Heart Association
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enrollment. The percentages of patients with a documented
LDL-C level were presented among all patients, primary
prevention patients, and secondary prevention patients,
respectively. The percentages of primary and secondary
prevention patients with LDL-C documented were compared
using the chi-square test.
Patient, clinician, and practice characteristics (including
subspecialty, guideline adoption, and practice location), core
laboratory lipid measurements, and statin usage were summarized using percentage for categorical variables and
median (ﬁrst quartile, third quartile) for continuous variables
and compared between patients with and without a documented LDL-C using the chi-square test for all categorical
variables and the Wilcoxon rank-sum test for continuous
variables. The lipid measurements were also presented and
compared among primary and secondary prevention patients,
respectively.
We then assessed the association between documented
LDL-C and statin use (yes or no) at the visit among patients
with a guideline indication for statin treatment using a
generalized estimating equations logistic regression model.
This was implemented with a compound symmetric working
correlation matrix and empirical (sandwich) standard error
estimates, adjusting for clustering of observations from the
same hospital. The covariates for risk adjustment consisted of
age ﬁtted with restricted cubic spline terms with 3 knots at
10%, 50%, and 90% of the empirical distribution; sex; race
(black versus nonblack); body mass index with restricted
cubic spline terms with three knots at 10%, 50%, and 90% of
the empirical distribution; smoking status (current, quit within
past year, quit >1 year ago; or never smoker); hypertension;
diabetes mellitus (diabetes mellitus requiring insulin, diabetes
mellitus without insulin, and no diabetes mellitus); prior
ASCVD; family history of ASCVD; chronic kidney disease; and
insurance status (private, government versus none). The
percentage of missing values are rare, <2.5% for all variables
in the multivariable model, with most of the variables for the
risk adjustment missing less than 0.5%. For continuous
variables such as age and body mass index, we imputed the
missing values to the median value. For categorical variables,
the missing values were imputed using mode values.
A P value of <0.05 was considered signiﬁcant. All
statistical analyses were performed using SAS version 9.4
(SAS Institute, Inc, Cary, NC).
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Table 1. Patient Characteristics and Lipid Testing Before Enrollment
Patients With a Medical Record–Documented LDL-C in Past 2 Years
Yes n=4840 (63.5%)

No n=2787 (36.5%)

P Value

Age: median (Q1, Q3)

68 (60, 74)

68 (59, 75)

0.73

Age ≥75 y

25.0%

25.9%

0.35

Female

46.2%

49.5%

0.006

Demographics

Nonwhite race

11.2%

21.7%

<0.001

Private insurance

64.4%

47.1%

<0.001

Uninsured

1.4%

3.8%

<0.001

College graduate or higher

38.4%

32.1%

<0.001

44.5%

40.5%

<0.001

36.8%

33.6%

0.005

Medical history
Prior ASCVD*
Prior CAD
Prior PAD

†

‡

8.8%

8.1%

0.31

Cerebrovascular disease§

13.3%

12.5%

0.29

Diabetes mellitus

37.7%

40.0%

0.04

Hypertension

76.3%

79.3%

0.002

Current/recent smoker

10.6%

18.3%

<0.001

Chronic kidney disease

10.8%

7.1%

<0.001

15.5%

12.6%

<0.001

BMI: median (Q1, Q3)

29.7 (26.1, 34.1)

29.8 (26.1, 34.7)

0.32

Family history of premature ASCVD

10.6%

7.1%

<0.001

Predicted 10 y ASCVD risk (among
primary prevention patients)

11.7 (5.7, 20.9)

13.8 (7.1, 23.6)

<0.001

Thyroid disease

k
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P values are based on chi-square tests for all categorical variables and Wilcoxon rank-sum tests for all continuous variables. ASCVD indicates atherosclerotic cardiovascular disease; BMI,
body mass index; CAD, coronary artery disease; LDL-C, low-density lipoprotein cholesterol; PAD, peripheral artery disease; Q1, quarter 1; Q3, quarter 3.
*ASCVD: deﬁned as patients with prior CABG, PCI, myocardial infarction, CAD, stroke, carotid artery stenosis, abdominal aortic aneurysm, PAD or non-coronary revascularization.
†
CAD: deﬁned as patients with prior CABG, PCI, history of myocardial infarction, or known CAD.
‡
PAD: including PAD, noncoronary arterial revascularization, and abdominal aortic aneurysm.
§
Cerebrovascular disease: including carotid artery stenosis, stroke, or transient ischemic attack.
k
Thyroid disease: includes both hypothyroid and hyperthyroid disease.

statin at a dose lower than the guideline-recommended
intensity. More than one third of patients who were either not
on a statin or underdosed (38.0%) had no clinician-ordered LDL-C
measures in the past 2 years. Among patients indicated for
secondary prevention statin therapy, 536 (16.3%) were not on a
statin at the time of enrollment (Table 3), and 43.1% of those
prescribed a statin were underdosed, according to the 2013
ACC/AHA guideline recommendations. Again, more than one
third of secondary prevention patients who were either not on a
statin or underdosed (34.3%) had no LDL-C measures in the
past 2 years.

Association of Lipid Testing With LDL-C Levels
Core laboratory testing of patients enrolled in the PALM
registry revealed 166 individuals (2.2% of the overall study

DOI: 10.1161/JAHA.118.009251

population) with LDL-C levels ≥190 mg/dL. Of these
patients, 36.1% had no LDL-C measurement in the prior
2 years, and 57.2% were not on a statin at the time of
enrollment.
In patients with a guideline indication for statin therapy,
those with chart-documented LDL-C testing in the prior
2 years had lower core laboratory LDL-C levels at the time
of enrollment than those without (median 92 versus 97 mg/
dL; P<0.001). When subset to patients on statin therapy,
those with prior LDL-C testing had lower core laboratory
LDL-C, non-HDL, and triglyceride levels at enrollment
compared with those without lipid testing, regardless of
primary prevention indication (Table 2) or secondary prevention indication (Table 3). Among adults on statins for
secondary prevention, 1897 (69.1%) and 715 (26.0%) still
had core laboratory LDL-C levels ≥70 and 100 mg/dL at the
Journal of the American Heart Association
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100

p=0.003
% Patients with Chart-Documented LDL-C
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p=0.06
p<0.001

p<0.001

p<0.001

p<0.001

74.4
69.5

67.2
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68.3

64.7

68.2

60.7

65.5
60.6

60
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44.5
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20

10

0
Endocrinology

Endocrinology

Cardiology

Cardiology

PrimaryCare
Care

Primary

Provider Specialty

≤ 5 years

6-20 years

≤ 5 Years
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> 20 years

> 20 Years

Years in Pracce

Provider Specialty

Years in Pracce

2013
Other
2013
ACC/AHA
Other
Guideline
Guideline Preference*
ACC/AHA
Guideline

Guideline Preference*

Urban

Urban

Rural

Rural

Pracce Locaon

Pracce Locaon

Figure 1. Proportion of patients with lipid testing before enrollment stratiﬁed by clinician and practice characteristics. *Guideline preference:
clinicians were asked to identify the guideline used primarily in management of their patients by choosing from (1) 2013 ACC/AHA guideline,
(2) ATP III, (3) AACE guidelines, (4) International Atherosclerosis Society recommendations, (5) ESC/EAS guidelines, (6) National Kidney Foundation—
KDOQI clinical practice guidelines for managing dyslipidemias in chronic kidney disease, (7) Other, and (8) None. Prefer other guidelines
encompasses choices 2 to 8. Practice location determined from site zip code. AACE indicates American Association of Clinical Endocrinologists;
ACC, American College of Cardiology; AHA, American Heart Association; ATP III, Adult Treatment Panel III; EAS, European Atherosclerosis
Society; ESC, European Society of Cardiology; KDOQI, National Kidney Foundation Kidney Disease Outcomes Quality Initiative.
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time of enrollment, respectively. Of the patients with LDL-C
≥100 mg/dL, 36.1% had not undergone lipid testing in the
past 2 years.

60.0
50.0

p=0.016

p=0.037

40.0
30.0

24.3

27.3
21.5

24.8

20.0
10.0
0.0

On Stan

On High Intensity Stan

Lipid Tesng

On Non-Stan Lipid Lowering
Therapy

No Lipid Tesng

Figure 2. Prior LDL-C testing and statin use. On statin: total
percentage of patients, with guideline recommendation for statin
therapy, treated with statin medication. On high-intensity statin:
total percentage of patients, with guideline recommendation for
statin therapy, treated with high-intensity statin medication. On
nonstatin lipid-lowering therapy: total percentage of patients, with
guideline recommendation for statin therapy, treated with nonstatin lipid-lowering therapy including ezetimibe, ﬁbrate, niacin,
ﬁsh oil, or bile acid sequestrant.
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Discussion
This analysis of the PALM registry aimed to evaluate current
LDL-C testing patterns in patients treated at cardiology,
endocrinology, and primary care practices across the United
States. We observed that (1) more than one third of patients
in community practice had no LDL-C levels measured in the
past 2 years; (2) rates of LDL-C testing varied as a function of
patient race, sex, and socioeconomic status, as well as by
whether the patient was seen by a specialist or primary care
provider; (3) among patients recommended for but either not
on a statin or prescribed a statin at less than guidelinerecommended intensity, more than one third had no LDL-C
testing in the prior 2 years; and (4) patients with recent lipid
testing were more likely to be treated with statin therapy and
had lower LDL-C and non–HDL-C levels.
The 2013 ACC/AHA cholesterol guidelines moved away
from achieving target LDL-C levels8 toward a focus on
implementing the appropriate intensity of statin therapy on
the basis of underlying cardiovascular disease risk.9 Recommendations for LDL-C testing remain in these guidelines to
screen for familial hypercholesterolemia, determine response
to statin therapy, and assess adherence. Prior studies
demonstrated a misconception that clinicians following the
2013 ACC/AHA guidelines no longer needed to measure lipid
Journal of the American Heart Association
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Table 2. Core Laboratory Measurements Among Patients Indicated for Primary Prevention Statin Therapy
Indicated for Primary Prevention Statin Therapy (n=2627)
Statin Use

On Statin (n=1672)

Not on Statin (n=955)

Prior LDL-C Testing

Yes (n=1043)

No (n=629)

P Value

Yes (n=574)

No (n=381)

P Value

Core laboratory LDL-C ≥100 mg/dL
at enrollment

420 (40.3%)

302 (48.0%)

0.002

455 (79.3%)

293 (76.9%)

0.38

Core laboratory LDL-C ≥130 mg/dL
at enrollment

154 (14.8%)

126 (20.0%)

0.005

256 (44.6%)

156 (40.9%)

0.26

Median LDL-C (Q1, Q3)

92 (73, 114)

98 (79, 122)

<0.001

125 (103, 148)

123 (101, 144)

0.24

Median HDL-C (Q1, Q3)

51 (43, 63)

52 (42, 63)

0.47

55 (45, 67)

54 (44, 66)

0.50

Median triglycerides (Q1, Q3)

136 (96, 195)

144 (103, 212)

0.01

143.5 (105, 200)

143 (100, 221)

0.50

Median non–HDL-C (Q1, Q3)

112 (89, 135)

120 (98, 148)

<0.001

146 (122, 175)

145.0 (123, 172)

0.91

P values are based on chi-square tests for all categorical variables and Wilcoxon rank-sum tests for all continuous variables. HDL-C indicates high-density lipoprotein cholesterol; LDL-C,
low-density lipoprotein cholesterol; Q1, quarter 1; Q3, quarter 3.
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levels given the shift away from LDL-C treatment targets.12,13
Our study showed that many primary and secondary prevention patients were managed without recent LDL-C testing,
which may be a reﬂection of misinterpretation of the 2013
ACC/AHA guidelines. Endocrinologists had the highest rate of
LDL-C testing, followed by cardiologists and then primary care
providers. Clinicians who reported primarily following the
2013 ACC/AHA cholesterol guidelines were more likely to
test LDL-C levels.
More than one third of patients in our study of community
practice had no evidence of recent LDL-C testing. We also
observed disparities in lipid testing: Patients without lipid
testing were more often women, nonwhite, uninsured, or less
educated than those with testing. While all patients in our
study were seen in an outpatient clinic, lower socioeconomic
status, barriers to routine health maintenance care, lack of
access to specialty care, and lower health literacy may explain

these ﬁndings.14 Disparities in testing may also contribute to
undertreatment in these sociodemographic subgroups.
With the release of the 2013 ACC/AHA guideline, a larger
population of patients in the United States are now indicated
for statin treatment,15–17 but prior studies show a considerable number of patients who were either untreated or
underdosed.18,19 Core laboratory results for the PALM registry
identiﬁed a group of adults with LDL-C ≥190 mg/dL who may
have been undiagnosed and untreated because LDL-C levels
had not been measured. More than one third of primary and
secondary prevention patients who were indicated for statin
therapy but were either untreated or treated below the
guideline-recommended dose did not have LDL-C testing in
the past 2 years. These groups of patients may have
beneﬁted from lipid testing to assess candidacy for statin
treatment, appropriateness of statin dosing, adherence to
treatment, and potential eligibility for nonstatin lipid-lowering

Table 3. Core Laboratory Measurements Among Patients Indicated for Secondary Prevention Statin Therapy
Patients With Prior ASCVD (n=3282)
Statin Use

On Statin (n=2746)

Prior LDL-C Testing

Yes (n=1823)

No (n=923)

P Value

Not on Statin (n=536)
Yes (n=330)

No (n=206)

P Value

Core laboratory LDL-C ≥100 mg/dL
at enrollment

457 (25.1%)

258 (28.0%)

0.10

237 (71.8%)

143 (69.4%)

0.55

Core laboratory LDL-C ≥130 mg/dL
at enrollment

123 (6.7%)

93 (10.1%)

0.002

149 (45.2%)

69 (33.5%)

0.008

Median LDL-C (Q1, Q3)

80 (65, 100)

83 (67, 103)

0.02

123 (95, 151)

117.5 (94, 140)

0.14

Median HDL-C (Q1, Q3)

49 (42, 59)

50 (40, 61)

0.95

51 (42, 66)

49 (41, 61)

0.08

Median triglycerides (Q1, Q3)

131 (93, 184)

140 (101, 198)

<0.001

137 (100, 195)

142 (99, 214)

0.27

Median non–HDL-C (Q1, Q3)

99 (81, 122)

102 (84, 128)

0.001

142 (114, 173)

139.5 (115, 168)

0.50

P values are based on chi-square tests for all categorical variables and Wilcoxon rank-sum tests for all continuous variables. ASCVD indicates atherosclerotic cardiovascular disease; HDLC, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; Q1, quarter 1; Q3, quarter 3.
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may help to optimize adherence to guideline-recommended
statin use and dosing, as well as identify patients who are
nonadherent to treatment or who need more intense lipidlowering therapy.
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Conclusion
More than one third of patients with or at risk for ASCVD are
treated in contemporary practice without provider knowledge
of LDL-C levels within the previous 2 years. Knowledge of
LDL-C test results is associated with increased guideline
adherence to statin therapy and better lipid control in both
primary and secondary prevention populations. Lipid testing
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